Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTacP
- Development stage
- Unknown
- Lead developer
- Institute of Medical Biology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTacP is an investigational Diphtheria-Tetanus-acellular Pertussis (component) combined vaccine developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (IMB-CAMS). Unlike traditional co-purified DTaP vaccines, which are produced by purifying the supernatant of Bordetella pertussis cultures, DTacP is a "component" vaccine. This means it is formulated using individually purified and precisely measured antigens, specifically pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin (PRN), alongside diphtheria and tetanus toxoids. This approach is intended to provide better control over the vaccine's composition, potentially leading to more consistent immunogenicity and a reduced reactogenicity profile. The vaccine is currently being evaluated in Phase I clinical trials for safety and immunogenicity in children aged 2 months to 6 years.
- Other names
- Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
02
Targets
PRN (Pertactin)PT (Pertussis toxin)FHA (Filamentous hemagglutinin)BCR (Immunoglobulin G B Cell Receptor)Diphtheria toxinETV6 (ETS variant transcription factor 6)
Beyond the preview
Go deeper on DTacP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTacP.